Template:Nadolol: Difference between revisions

Latest revision as of 21:07, 5 February 2014

Nadolol
CORGARD^® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Nadolol
ClinicalTrials.gov

@@ Line 2: / Line 2: @@
 ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Nadolol|{{fontcolor|#6C7B8B|Nadolol}}]]'''''
 |-
-! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ZZZZZ<sup>®</sup> FDA Package Insert
+! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | CORGARD<sup>®</sup> FDA Package Insert
 |-
 ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Nadolol indications and usage|Indications and Usage]]
 |-
 ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Nadolol dosage and administration|Dosage and Administration]]
-|-
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Nadolol dosage forms and strengths|Dosage Forms and Strengths]]
 |-
 ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Nadolol contraindications|Contraindications]]